JFJavier Fernandez

Javier Fernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Javier Fernandez has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Specific IgG Antibodies to Penicillin and Anaphylaxis

    by Miguel Blanca, Javier Fernandez, Natalia Blanca‐Lopez, Angel Esteban


  • Open Access

    Utility of the Basophil Reactivity Test in the Clinical Management of People with Severe Uncontrolled Asthma

    by Maria del Mar García Ródenas, Luis Manuel Hernández Blasco, Francisco Javier Fernández Sánchez, Francisco Manuel Marco de la Calle, Jose-Francisco Pascual-Lledó, Ángel Sánchez Barbie, Cleofé Fernández Aracil

    Introduction: The prognosis of asthma has improved significantly since the availability of monoclonal antibodies (mAbs). However, there are no robust predictive markers of response to help clinicians select one of the multiple biologicals recommended in clinical practice guidelines. The aim of this study was to evaluate the utility of basophil reactivity, measured through the basophil activation test (BAT), as a marker of response to mAbs. Methods: We measured basophil reactivity, using anti-immunoglobulin E (anti-IgE) antibodies as a stimulus, in 72 consecutive patients with severe uncontrolled asthma before initiation of treatment with mAbs. Forty-nine patients received omalizumab, 28 received mepolizumab, and 23 received benralizumab at some point. The Spanish Asthma Management Guidelines (GEMA) informed clinical management throughout the study. We studied clinical characteristics, laboratory values, and measures of respiratory function and asthma control. Results: Basophil reactivity (at the highest anti-IgE dilution at which basophil activation was positive) was inversely associated with asthma control and response to any mAb. The patients with higher basophil reactivity (≥ 29% versus < 29%) had lower mAb complete response, more frequent mAb switches, and worse baseline lung function and Asthma Control Test (ACT) scores. The BAT was associated with poor response above the cut-off values of 10.5% for mepolizumab, 15.5% for omalizumab, and 28% for benralizumab. Conclusion: Patients with basophil reactivity greater than or equal to 29% were less likely to achieve full control of asthma when treated with omalizumab, mepolizumab, or benralizumab, independently of classic clinical or biological markers of type 2 asthma.


  • Open Access

    Cytokine Variations After Positive Oral Food Challenges in Adult‐Onset Food Protein‐Induced Enterocolitis

    by Purificacion Gonzalez‐Delgado, Sara Anvari, Ana I. Jimenez, Paulina Gallego‐Velez, Cristina Sanchez‐Fortun, Teodorikez‐Wilfox Jimenez‐Rodriguez, Francisco Marco de la Calle, Javier Fernandez, Jordi Barrachina


  • Open Access

    Influence of inputs from foreign source regions on daily profiles of Olea pollen at an urban site in the southeast of the Iberian Peninsula

    by S. Martinez-Pérez, J.F. Nicolás, N. Galindo, F.J. Fernández-Sanchez, V. Soriano-Gomis, M. Varea

  • Open Access

    Food protein-induced enterocolitis syndrome in adults: review and practice recommendations

    by Purificación González-Delgado, Ana Entrala, Ramon Nuñez-Orjales, Eva Marchan, Javier Fernández, Anna Nowak-Wegrzyn

    Food protein-induced enterocolitis syndrome (FPIES) is an allergic disorder that manifests as reproducible gastrointestinal symptoms within hours of ingestion of the causative food, which can progress to dehydration and hypotension. Historically, FPIES has been recognized as a disease affecting the pediatric population but it can also develop de novo in adults. The pathophysiology is not well understood; however, the local adaptive immune system and gene expression linked to innate immune activation are implicated. Adult-onset FPIES has some differences with pediatric FPIES. Vomiting may be absent, while abdominal pain is the most common manifestation. A clear predominance in women occurs, being seafood the most common trigger, although many other foods have also been implicated. Diagnosis of adult-onset FPIES is based on a thorough clinical history but in many cases, it should be followed by an oral food challenge (OFC), due to the absence of vomiting in some patients and the lack of confirmatory diagnostic test. The first-line treatment for acute FPIES reactions is fluid replacement, by the oral route in mild to moderate reactions or via the intravenous route in severe reactions. Ondansetron may be effective in shortening the duration of emesis. Management of patients after diagnosis includes dietary advice and follow-up with supervised OFC at regular intervals to monitor for resolution. Tolerance to the trigger food in children is commonly achieved, a finding not so common in adult-onset FPIES. The aim of this article is to review the most important current concepts in epidemiology, pathophysiology, diagnosis, and management of FPIES.


  • Open Access

    Validation of the new microarray platform ALEX for specific IgE detection of respiratory and plant-food allergens

    by Paola Quan, Marina Sabate-Bresco, Carmen D'Amelio, Mariona Pascal, Blanca Garcia, Gabriel Gastaminza, Natalia Blanca-Lopez, Maria Alvarado, Javier Fernandez, Carmen Moya, et al.

    Background: As the use of multiplex specific IgE (sIgE) detection methods becomes increasingly widespread, proper comparative validation assessments of emerging new platforms are vital. The objective of this study was to assess the clinical and technical performance of the ALEX platform (MacroArray Diagnostics), in comparison to the ImmunoCAP ISAC 112 microarray and the ImmunoCAP singleplex method (ThermoFisher Scientific) in the diagnosis of pollen (cypress, grass, olive), dust mite Dermatophagoides pteronyssinus, Alternaria alternata, fruit (apple, peach) and nut (walnut, hazelnut and peanut) allergy. Methods: We enrolled 153 allergic patients and 16 non-atopic controls. sIgE assays were conducted using ISAC112, ALEX version 2 (ALEX2), and ImmunoCAP for whole extracts and major components. Technical validation of ALEX2 was performed by measuring repeatability and inter-assay, inter-batch and inter-lab reproducibility. Results: When measured globally (detection by one or more allergen components), ALEX2 showed adequate sensitivity and specificity for most of the allergens studied, comparable in general to that of ISAC112 (except for olive pollen and walnut) and similar to that of ImmunoCAP whole extract measurements. Component-by-component analysis showed comparable results for all techniques, except for Ole e 1 and Jug r 3 in both ISAC112 and ImmunoCAP comparisons, and Alt a 1, when compared with ISAC112. Continuous sIgE levels correlate with sIgE by ImmunoCAP. Good reproducibility and repeatability were observed for ALEX2. Conclusions: ALEX2 shows sound technical performance, and adequate diagnostic capacity, comparable in general to that of ISAC112 and ImmunoCAP for some aeroallergens and plant-food allergies in Mediterranean patients.

  • CO108 - IMPACTO DE LA 18F-DCFPYL (PSMA) PET/TC EN LA DETECCIÓN Y MANEJO TERAPÉUTICO DE LA RECIDIVA BIOQUÍMICA DEL CÁNCER DE PRÓSTATA

    by Javier Fernández Fernández, Eva María Triviño Ibáñez, Daniel José Rivas Navas, Jose Luis Villa Palacios, Antonio Rodríguez Fernández

  • CO010 - IMPACTO DE LA [18F]F-FLUOROCLINA PET/TC EN EL MANEJO Y PRONÓSTICO DEL CARCINOMA HEPATOCELULAR

    by Daniel José Rivas Navas, Javier Fernández Fernández, Eva María Triviño Ibáñez, Jose Luis Villa Palacios, Antonio Rodríguez Fernández

  • P127 - ANÁLISIS COMPARATIVO DEL ESTUDIO PRECOZ Y TARDÍO DE LA [18F]F-FLUOROCOLINA PET/TC EN LA VALORACIÓN DEL CARCINOMA HEPATOCELULAR

    by Daniel José Rivas Navas, Eva María Triviño Ibáñez, Javier Fernández Fernández, Jose Luis Villa Palacios, Antonio Rodríguez Fernández

  • Open Access

    Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes and management with desensitization.

    by Teodorikez Jimenez-Rodriguez, Leticia De Las Vecillas Sánchez, Marina Labella, Donna-Marie Lynch, Kylie Marie Besz, Kathleen Marquis, Amparo Burgos, Victor Soriano Gomis, Inmaculada Lozano, Rosa Ana Montoyo Antón, et al.

    Background Drug hypersensitivity reactions (DHRs) to platinum-based drugs are heterogenous and restrict their access, and drug desensitization (DD) has provided a ground-breaking procedure for their re-introduction, although the response is heterogeneous. We aimed to identify the phenotypes, endotypes and biomarkers of reactions to carboplatin and oxaliplatin and their response to DD. Methods Seventy-nine patients presenting with DHRs to oxaliplatin (N=46), and carboplatin (N=33) were evaluated at the Allergy Departments of two tertiary care hospitals in Spain. Patient symptoms, skin testing, biomarkers, and outcomes of 267 DDs were retrospectively analyzed. Results Oxaliplatin-reactive patients presented with type I (74%), cytokine release reaction (CRR) (11%), and mixed (Mx) (15%) phenotypes. In contrast, carboplatin reactive patients presented with predominantly type I (85%) and Mx (15%) but no CRRs. Out of 267 DDs, breakthrough reactions (BTRs) to oxaliplatin occurred twice as frequently as carboplatin (32% versus 15%; pConclusion Carboplatin and oxaliplatin induced three different types of reactions with defined phenotypes and endotypes amendable to DD. Although most of the initial reactions for both were type I, oxaliplatin presented with unique CRR reactions. During DD, carboplatin reactive patients presented mostly type I BTR, while oxaliplatin reactive patients frequently switched from type I to CRR, providing a critical difference and the need for personalized DD protocols.